Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and meaningful, especially for those of you who managed to survive the annual trek to the J.P. Morgan conference. Now that all the excitement is in the rear view mirror, the time has come to focus on the tasks ahead — meetings, deadlines, and the usual what-not. So please join us as we reach for a needed cup of stimulation and dig in for another busy day. Hope yours goes well and, of course, do keep in touch. We appreciate the tips and insights. …

Sen. Cory Booker (D-N.J.) is trying to overcome doubts that he is too close to the pharmaceutical industry ahead of an expected presidential campaign, The Hill says. The progressive criticism reached a crescendo in early 2017 when he voted against a budget amendment calling for importing drugs from abroad. But last week, Booker attempted to show he is tough on drug companies, appearing alongside Sen. Bernie Sanders (I-Vt.), a potential presidential rival, at a press conference on lowering drug prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.